论文部分内容阅读
2003年,MOSAIC研究的发表使FOLFOX方案成为结直肠癌辅助化疗的新选择。在2004年ASCO会议上,以希罗达单药口服与静脉推注5-FU/CF辅助化疗进行比较的X-ACT研究初见报告,希罗达以疗效好,不良反应轻,使用方便,且有更好的药物经济学评价而获首肯。2005年NEJM上报告了X-ACT研究中位随访4.3年(51个月)的结果,希罗达单药口服与静脉推注5-FU/CF方案相比,在无病生存率(DFS)、总生存率、3年
In 2003, the publication of the MOSAIC study made FOLFOX a new option for adjuvant chemotherapy for colorectal cancer. In 2004 ASCO meeting, Xeloda single oral and intravenous injection of 5-FU / CF adjuvant chemotherapy compared to the initial report of X-ACT, Xeloda to good effect, adverse reactions, ease of use, And there is a better pharmacoeconomic evaluation and approval. In 2005, NEJM reported a median follow-up of 4.3 years (51 months) in the X-ACT study. Compared with intravenous bolus 5-FU / CF regimen, Overall survival rate, 3 years